Acuity Medical

Recruitment of clinical sites begins for TheraMac trial in age-related macular degeneration

Published in Pharma Law Weekly, November 22nd, 2005

Acuity Medical is planning for the recruitment of clinical sites in the United States for their pivotal premarket clinical (PMA) trial for TheraMac, a medical device for the treatment of dry age-related macular degeneration (AMD).

AMD is the leading cause of legal blindness effecting more than 50 million people worldwide. Currently there is no effective treatment for dry AMD.

TheraMac has already successfully completed a proof of concept U.S. Food and Drug Administration (FDA) trial which showed that in 2 weeks 26% of the eyes treated had improved vision by 10 letters or more, the equivalent of two lines on the eye chart. TheraMac has also been the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2005-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry